CompITO: Rush vs Conventional Oral Immunotherapy in Milk and Egg Allergic Children

Phase 3, randomised, open-label trial in Cow's milk allergy (CMA) and Hen's Egg Allergy (2 arms). Primary endpoints: Number of adverse events with an oFASS5 severity >=2 occurred until Induction Phase completion at the hospital setting at 7 months and Proportion of subjects completing the Induction Phase at 7 months. Started Jun 2025; status: recruiting.